Jon Wigginton: Very exciting phase 3 data regarding stage 3 melanoma
Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn:
“NEJM and ASCO with very exciting randomized Phase 3 data regarding the role of neoadjuvant nivolumab and ipilimumab (2 neoadjuvant doses!) with surgery and response-directed adjuvant nivolumab versus surgery/adjuvant nivolumab in patients with stage 3 melanoma.
Event free survival rate at 12 months 83.7% in neoadjuvant arm vs 57.2% in surgery/adjuvant nivolumab.
Hazard ratio for progression, recurrence or death=0.32. Major pathologic responses in 59% of patients who received at least 1 dose of neoadjuvant immunotherapy, including 47.2% who achieved a pathologic CR.
Fantastatic news for patients, and great evidence that putting the right IO tools together the right way, even with a very short course of therapy, can mobilize the immune system in a powerful manner to deliver clinical benefit.
Also, further evidence that in combination therapy, creativity in dosing and scheduling wins the day (roughly the equivalent of 1 mg/kg of ipi and 3mg/kg nivo).
Recall that both drugs were initially approved as monotherapy at doses of 3mg/kg.
Congratulations to all involved!”
Additional information.
Source: Jon Wigginton/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023